High-risk prostate cancer: A disease of genomic instability

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1101-1107

  Tapia Laliena, María A ^a   Korzeniewski, Nina ^a   Hohenfellner, Markus ^a   Duensing, Stefan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarkers; DNA damage; Genomic instability; Prostate cancer; Somatic mutations; Translational therapeutics

Indexed keywords

ADVANCED CANCER; ANEUPLOIDY; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER RISK; CHROMOPLEXY; CHROMOSOME DISORDER; CHROMOSOME REARRANGEMENT; CHROMOTHRIPSIS; COPY NUMBER ALTERATION; DNA DAMAGE; DNA DAMAGE CHECKPOINT; GENE AND NUCLEIC ACID PARAMETERS; GENE FUSION; GENOMIC INSTABILITY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SOMATIC MUTATION; ANIMAL; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; GENETICS; PROGNOSIS; PROSTATE TUMOR;

ANIMALS; DISEASE PROGRESSION; DNA DAMAGE; GENOMIC INSTABILITY; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84925938622     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.02.005     Document Type: Review

References (60)

1. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
2. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
3. Braun M., Stomper J., Kirsten R., Shaikhibrahim Z., Vogel W., Bohm D., et al. Landscape of chromosome number changes in prostate cancer progression. World J Urol 2013, 31:1489-1495.
4. Cahill D.P., Kinzler K.W., Vogelstein B., Lengauer C. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999, 9:M57-M60.
5. Zhang C.Z., Leibowitz M.L., Pellman D. Chromothripsis and beyond: rapid genome evolution from complex chromosomal rearrangements. Genes Dev 2013, 27:2513-2530.
6. Cuevas R., Korzeniewski N., Tolstov Y., Hohenfellner M., Duensing S. FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57. Cancer Res 2013, 73:1400-1410.
7. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30:1073-1081.
8. Kaelin W.G. Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med 2009, 1:99.
9. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525. The Cancer Genome Atlas Research Network.
10. Berger M.F., Hodis E., Heffernan T.P., Deribe Y.L., Lawrence M.S., Protopopov A., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
11. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
12. Kumar A., White T.A., MacKenzie A.P., Clegg N., Lee C., Dumpit R.F., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A 2011, 108:17087-17092.
13. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012, 44:685-689.
14. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
15. Beltran H., Yelensky R., Frampton G.M., Park K., Downing S.R., MacDonald T.Y., et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013, 63:920-926.
16. Weischenfeldt J., Simon R., Feuerbach L., Schlangen K., Weichenhan D., Minner S., et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013, 23:159-170.
17. Schaefer G., Mosquera J.M., Ramoner R., Park K., Romanel A., Steiner E., et al. Distinct ERG rearrangement prevalence in prostate cancer: higher frequency in young age and in low PSA prostate cancer. Prostate Cancer Prostatic Dis 2013, 16:132-138.
18. Goodwin J.F., Schiewer M.J., Dean J.L., Schrecengost R.S., de Leeuw R., Han S., et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 2013, 3:1254-1271.
19. Polkinghorn W.R., Parker J.S., Lee M.X., Kass E.M., Spratt D.E., Iaquinta P.J., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013, 3:1245-1253.
20. Castro E., Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl 2012, 14:409-414.
21. Leongamornlert D., Mahmud N., Tymrakiewicz M., Saunders E., Dadaev T., Castro E., et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer 2012, 106:1697-1701.
22. Bednarz N., Eltze E., Semjonow A., Rink M., Andreas A., Mulder L., et al. BRCA1 loss preexisting in small subpopulations of prostate cancer is associated with advanced disease and metastatic spread to lymph nodes and peripheral blood. Clin Cancer Res 2010, 16:3340-3348.
23. Castro E., Goh C., Olmos D., Saunders E., Leongamornlert D., Tymrakiewicz M., et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013, 31:1748-1757.
24. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
25. Liu W., Xie C.C., Thomas C.Y., Kim S.T., Lindberg J., Egevad L., et al. Genetic markers associated with early cancer-specific mortality following prostatectomy. Cancer 2013, 119:2405-2412.
26. El Gammal A.T., Bruchmann M., Zustin J., Isbarn H., Hellwinkel O.J., Kollermann J., et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clin Cancer Res 2010, 16:56-64.
27. Reid A.H., Attard G., Ambroisine L., Fisher G., Kovacs G., Brewer D., et al. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010, 102:678-684.
28. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
29. Barlow J.H., Faryabi R.B., Callen E., Wong N., Malhowski A., Chen H.T., et al. Identification of early replicating fragile sites that contribute to genome instability. Cell 2013, 152:620-632.
30. Bunting S.F., Callen E., Wong N., Chen H.T., Polato F., Gunn A., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010, 141:243-254.
31. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
32. Perner S., Svensson M.A., Hossain R.R., Day J.R., Groskopf J., Slaughter R.C., et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010, 75:762-767.
33. Perner S., Demichelis F., Beroukhim R., Schmidt F.H., Mosquera J.M., Setlur S., et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 2006, 66:8337-8341.
34. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008, 8:497-511.
35. Klezovitch O., Risk M., Coleman I., Lucas J.M., Null M., True L.D., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008, 105:2105-2110.
36. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010, 42:668-675.
37. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
38. Zong Y., Xin L., Goldstein A.S., Lawson D.A., Teitell M.A., Witte O.N. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A 2009, 106:12465-12470.
39. Zhang S., Pavlovitz B., Tull J., Wang Y., Deng F.M., Fuller C. Detection of TMPRSS2 gene deletions and translocations in carcinoma, intraepithelial neoplasia, and normal epithelium of the prostate by direct fluorescence in situ hybridization. Diagn Mol Pathol 2010, 19:151-156.
40. Pettersson A., Graff R.E., Bauer S.R., Pitt M.J., Lis R.T., Stack E.C., et al. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev 2012, 21:1497-1509.
41. Brase J.C., Johannes M., Mannsperger H., Falth M., Metzger J., Kacprzyk L.A., et al. TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-beta signaling. BMC Cancer 2011, 11:507.
42. Borno S.T., Fischer A., Kerick M., Falth M., Laible M., Brase J.C., et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012, 2:1024-1035.
43. Kacprzyk L.A., Laible M., Andrasiuk T., Brase J.C., Borno S.T., Falth M., et al. ERG induces epigenetic activation of Tudor domain-containing protein 1 (TDRD1) in ERG rearrangement-positive prostate cancer. PLoS One 2013, 8:e59976.
44. Brenner J.C., Ateeq B., Li Y., Yocum A.K., Cao Q., Asangani I.A., et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011, 19:664-678.
45. Wu C., Wyatt A.W., McPherson A., Lin D., McConeghy B.J., Mo F., et al. Poly-gene fusion transcripts and chromothripsis in prostate cancer. Genes Chromosomes Cancer 2012, 51:1144-1153.
46. Crasta K., Ganem N.J., Dagher R., Lantermann A.B., Ivanova E.V., Pan Y., et al. DNA breaks and chromosome pulverization from errors in mitosis. Nature 2012, 482:53-58.
47. Maher C.A., Wilson R.K. Chromothripsis and human disease: piecing together the shattering process. Cell 2012, 148:29-32.
48. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
49. Zack T.I., Schumacher S.E., Carter S.L., Cherniack A.D., Saksena G., Tabak B., et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013, 45:1134-1140.
50. Rausch T., Jones D.T., Zapatka M., Stutz A.M., Zichner T., Weischenfeldt J., et al. Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell 2012, 148:59-71.
51. Albertson D.G., Collins C., McCormick F., Gray J.W. Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369-376.
52. Duensing S., Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res 2002, 62:7075-7082.
53. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
54. Spruck C.H., Won K.A., Reed S.I. Deregulated cyclin E induces chromosome instability. Nature 1999, 401:297-300.
55. Pihan G.A., Purohit A., Wallace J., Malhotra R., Liotta L., Doxsey S.J. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001, 61:2212-2219.
56. Toma M.I., Friedrich K., Meyer W., Frohner M., Schneider S., Wirth M., et al. Correlation of centrosomal aberrations with cell differentiation and DNA ploidy in prostate cancer. Anal Quant Cytol Histol 2010, 32:1-10.
57. Schatten H., Wiedemeier A.M., Taylor M., Lubahn D.B., Greenberg N.M., Besch-Williford C., et al. Centrosome-centriole abnormalities are markers for abnormal cell divisions and cancer in the transgenic adenocarcinoma mouse prostate (TRAMP) model. Biol Cell 2000, 92:331-340.
58. Magistroni V., Mologni L., Sanselicio S., Reid J.F., Redaelli S., Piazza R., et al. ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PLoS One 2011, 6:e28162.
59. Kibel A.S., Faith D.A., Bova G.S., Isaacs W.B. Xq27-28 deletions in prostate carcinoma. Genes Chromosomes Cancer 2003, 37:381-388.
60. Kasahara K., Taguchi T., Yamasaki I., Karashima T., Kamada M., Yuri K., et al. Fluorescence in situ hybridization to assess transitional changes of aneuploidy for chromosomes 7, 8, 10, 12, 16, X and Y in metastatic prostate cancer following anti-androgen therapy. Int J Oncol 2001, 19:543-549.